Back to 
Balyasny Asset Management L.P.
Balyasny Asset Management L.P.
HBIO
Showing 0 of 2 quarters
Position history for Balyasny Asset Management L.P.'s holdings in Harvard Bioscience, Inc.
No. Balyasny Asset Management exited its HBIO (Harvard Bioscience) position in Q4 2022. Its Q3 2022 13F listed 21,509 shares worth $55,000. Balyasny Asset Management first reported HBIO in Q3 2022 and held it in 1 quarterly 13F filing.
Current Value
—
Current Shares
—
Total Value Change
$0
Total Shares Change
0
No position history available for this security.